Literature DB >> 3886255

Kinetics of methylprednisolone and its hemisuccinate ester.

H Derendorf, H Möllmann, P Rohdewald, J Rehder, E W Schmidt.   

Abstract

Methylprednisolone in the form of its hemisuccinate ester was injected intravenously in doses of 10 mg/kg and 63.1 mg. Plasma levels of methylprednisolone and of the ester were measured and their kinetics were calculated. Results indicate dose dependency in the kinetics of both. About 10% of the dose was excreted unchanged as hemisuccinate in the urine, indicating incomplete conversion of the prodrug. When methylprednisolone (80 mg) was also taken by mouth, the relative bioavailability of the tablets was 99%. Saliva levels of methylprednisolone were low but paralleled plasma levels in the postdistribution phase. No methylprednisolone hemisuccinate was found in saliva.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886255     DOI: 10.1038/clpt.1985.79

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

Review 1.  Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics.

Authors:  Ana V Cheng; William M Wuest
Journal:  ACS Infect Dis       Date:  2019-04-10       Impact factor: 5.084

Review 2.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

3.  Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses.

Authors:  H Möllmann; P Rohdewald; J Barth; C Möllmann; M Verho; H Derendorf
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

4.  Methylprednisolone inhibits uptake of Ca2+ and Na+ ions into concanavalin A-stimulated thymocytes.

Authors:  F Buttgereit; S Krauss; M D Brand
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

Review 5.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 6.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

7.  Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat.

Authors:  Vivaswath S Ayyar; Dawei Song; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2019-06-13       Impact factor: 4.030

Review 8.  The role of human carboxylesterases in drug metabolism: have we overlooked their importance?

Authors:  S Casey Laizure; Vanessa Herring; Zheyi Hu; Kevin Witbrodt; Robert B Parker
Journal:  Pharmacotherapy       Date:  2013-02       Impact factor: 4.705

9.  Pharmacokinetics of triamcinolone acetonide and its phosphate ester.

Authors:  H Möllmann; P Rohdewald; E W Schmidt; V Salomon; H Derendorf
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response.

Authors:  P J Hayball; D G Cosh; M J Ahern; D W Schultz; P J Roberts-Thomson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.